Junior Lanzol Tablet

Description

Junior Lanzol Tablet, containing Lansoprazole 15mg, is manufactured by Cipla Ltd. and is available in Nepal at a retail price of 3.87 NPR per tablet. It is also available in 15mg and 30mg capsule forms under other brands. This medication is a proton pump inhibitor (PPI) used to reduce stomach acid and treat various acid-related conditions.

Dosage Information:

Adults (Oral, taken on an empty stomach before meals):

• Peptic Ulcer: 30 mg once daily in the morning for up to 4 weeks (duodenal ulcer) or up to 8 weeks (gastric ulcer). Maintenance: 15 mg/day.
• Zollinger-Ellison Syndrome: Initially, 60 mg once daily in the morning, adjusted as required. Daily doses >120 mg should be given in 2 divided doses.
• Acid-related Dyspepsia: 15-30 mg once daily in the morning for 2-4 weeks.
• Gastro-oesophageal Reflux Disease (GERD): 15-30 mg once daily in the morning for 4-8 weeks. Maintenance: 15-30 mg once daily according to response.
• Prophylaxis of NSAID-induced Ulcers: 15-30 mg once daily in the morning.
• H. pylori Infection: 1-week triple therapy: 30 mg twice daily (bid) combined with clarithromycin 500 mg bid and amoxicillin 1 g bid, OR combined with clarithromycin 250 mg bid and metronidazole 400 mg bid.
• Erosive Oesophagitis: 30 mg once daily in the morning for up to 8 weeks; an additional 8 weeks if not healed. Maintenance: 15 mg once daily.
• NSAID-associated Ulceration: 30 mg once daily in the morning for 4-8 weeks.
• Elderly: No dosage adjustment needed.
• Hepatic Impairment: Severe: Maximum 30 mg/day.

Children (Oral, taken on an empty stomach before meals):

• Gastro-oesophageal Reflux Disease & Erosive Oesophagitis:
  • 1-11 years:
    • <30 kg: 15 mg once daily in the morning for up to 12 weeks.

    • 30 kg: 30 mg once daily in the morning for up to 12 weeks.

    • Doses may be increased up to 30 mg twice daily if the patient is still symptomatic after 2 or more weeks of treatment.
  • 12-17 years: 15 mg once daily for up to 8 weeks (for GERD) or 30 mg once daily for up to 8 weeks (for erosive oesophagitis).

Renal Impairment: No dosage adjustment needed.

Important Considerations:

• Administration: Should be taken on an empty stomach, before meals.
• Contraindications: Do NOT use if you have hypersensitivity to Lansoprazole.
• Precautions: Use with caution in patients with hepatic impairment. Gastric malignancy should be ruled out before starting treatment. Use during pregnancy and lactation is generally not recommended as it’s not known if it’s distributed into breast milk.

Interactions with Other Medications:

• Increased risk of hypomagnesaemia with diuretics and digoxin.
• May decrease plasma concentration of erlotinib, dasatinib, and lapatinib.
• May decrease the bioavailability of itraconazole and ketoconazole.
• May increase plasma concentration of cilostazol and methotrexate.
• Reduced bioavailability with antacids and sucralfate.
• Potentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine and atazanavir.

Adverse Effects (Side Effects):

Common (1-10%):

• Headache (3-7%)
• Diarrhea (1-5%)
• Constipation (1-5%)
• Nausea (1-3%)
• Abdominal pain (1-3%)

Less Common (<1%):

• Anxiety, angina, palpitations, syncope, edema, anorexia, dry mouth, tenesmus, flatulence, melena, myalgia, tinnitus, allergic reaction.

Mechanism of Action:

Lansoprazole is a substituted benzimidazole, classified as a Proton Pump Inhibitor (PPI). It works by blocking the final step of acid secretion in the stomach by inhibiting the H+/K+ ATPase enzyme system within the gastric parietal cells. This effectively inhibits both basal and stimulated acid secretion.